Mechanism of FGF23 processing in fibrous dysplasia

Fibroblast growth factor‐23 (FGF23) is a phosphate‐ and vitamin D‐regulating hormone derived from osteoblasts/osteocytes that circulates in both active (intact, iFGF23) and inactive (C‐terminal, cFGF23) forms. O‐glycosylation by O‐glycosyl transferase N‐acetylgalactosaminyltransferase 3 (ppGalNAcT3) and differential cleavage by furin have been shown to be involved in regulating the ratio of active to inactive FGF23. Elevated iFGF23 levels are observed in a number of hypophosphatemic disorders, such as X‐linked, autosomal recessive, and autosomal dominant hypophosphatemic rickets, whereas low iFGF23 levels are found in the hyperphosphatemic disorder familial tumoral calcinosis/hyperphosphatemic hyperostosis syndrome. Fibrous dysplasia of bone (FD) is associated with increased total FGF23 levels (cFGF23 + iFGF23); however, classic hypophosphatemic rickets is uncommon. Our results suggest that it can be explained by increased FGF23 cleavage leading to an increase in inactive cFGF23 relative to active iFGF23. Given the fact that FD is caused by activating mutations in the small G‐protein Gsα that results in increased cyclic adenosine monophosphate (cAMP) levels, we postulated that there may be altered FGF23 cleavage in FD and that the mechanism may involve alterations in cAMP levels and ppGalNacT3 and furin activities. Analysis of blood specimens from patients with FD confirmed that the elevated total FGF23 levels are the result of proportionally increased cFGF23 levels, consistent with less glycosylation and enhanced cleavage by furin. Analysis of primary cell lines of normal and mutation‐harboring bone marrow stromal cells (BMSCs) from patients with FD demonstrated that BMSCs harboring the causative Gsα mutation had higher cAMP levels, lower ppGalNAcT3, and higher furin activity. These data support the model wherein glycosylation by ppGalNAcT3 inhibits FGF23 cleavage by furin and suggest that FGF23 processing is a regulated process that controls overall FGF23 activity in FD patients. © 2012 American Society for Bone and Mineral Research.

[1]  E. Farrow,et al.  Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice , 2011, Proceedings of the National Academy of Sciences.

[2]  Leah R. Padgett,et al.  Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. , 2011, The Journal of clinical endocrinology and metabolism.

[3]  Hiroyuki Tanaka,et al.  Fibroblast growth factor 23 concentrations in healthy term infants during the early postpartum period. , 2010, Bone.

[4]  M. Wolf,et al.  Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. , 2010, The Journal of clinical endocrinology and metabolism.

[5]  M. Razzaque,et al.  Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation , 2009, Proceedings of the National Academy of Sciences.

[6]  A. G. Semenov,et al.  Processing of pro-brain natriuretic peptide is suppressed by O-glycosylation in the region close to the cleavage site. , 2009, Clinical chemistry.

[7]  J. Weisel,et al.  Endocrine functions of bone in mineral metabolism regulation. , 2008, The Journal of clinical investigation.

[8]  T. Shawker,et al.  The role of type 1 and type 2 5'-deiodinase in the pathophysiology of the 3,5,3'-triiodothyronine toxicosis of McCune-Albright syndrome. , 2008, The Journal of clinical endocrinology and metabolism.

[9]  M. Razzaque,et al.  The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. , 2007, The Journal of endocrinology.

[10]  M. Collins,et al.  Determination of the elimination half-life of fibroblast growth factor-23. , 2007, The Journal of clinical endocrinology and metabolism.

[11]  Siu L. Hui,et al.  FGF23 Concentrations Vary With Disease Status in Autosomal Dominant Hypophosphatemic Rickets , 2007, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[12]  L. Bonewald,et al.  Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism , 2006, Nature Genetics.

[13]  T. Strom,et al.  Polypeptide GalNAc-transferase T3 and Familial Tumoral Calcinosis , 2006, Journal of Biological Chemistry.

[14]  K. White,et al.  The roles of specific genes implicated as circulating factors involved in normal and disordered phosphate homeostasis: frizzled related protein-4, matrix extracellular phosphoglycoprotein, and fibroblast growth factor 23. , 2006, Endocrine reviews.

[15]  P. Ureña,et al.  Recent findings in phosphate homeostasis , 2005, Current opinion in nephrology and hypertension.

[16]  S. Mooney,et al.  A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. , 2005, The Journal of clinical endocrinology and metabolism.

[17]  P. Orlik,et al.  An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. , 2005, Human molecular genetics.

[18]  T. Strom,et al.  FGF23 is processed by proprotein convertases but not by PHEX. , 2004, Bone.

[19]  D. Behar,et al.  Mutations in GALNT3, encoding a protein involved in O-linked glycosylation, cause familial tumoral calcinosis , 2004, Nature Genetics.

[20]  Y. Takeuchi,et al.  FGF‐23 Is a Potent Regulator of Vitamin D Metabolism and Phosphate Homeostasis , 2003, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  K. White,et al.  FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. , 2003, The Journal of clinical investigation.

[22]  Y. Takeuchi,et al.  Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. , 2002, The Journal of clinical endocrinology and metabolism.

[23]  T. Yoneya,et al.  Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophosphatemia in vivo. , 2002, Endocrinology.

[24]  S. Takeda,et al.  Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[25]  S. Wientroub,et al.  Renal Phosphate Wasting in Fibrous Dysplasia of Bone Is Part of a Generalized Renal Tubular Dysfunction Similar to That Seen in Tumor‐Induced Osteomalacia , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[26]  T. Meitinger,et al.  Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23 , 2000, Nature Genetics.

[27]  P. Bianco,et al.  Reproduction of human fibrous dysplasia of bone in immunocompromised mice by transplanted mosaics of normal and Gsalpha-mutated skeletal progenitor cells. , 1998, The Journal of clinical investigation.

[28]  L. Bonewald,et al.  Establishment of an Osteocyte‐like Cell Line, MLO‐Y4 , 1997, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[29]  L. Tabak,et al.  cDNA Cloning and Expression of a Novel UDP-N-acetyl-d-galactosamine:PolypeptideN-Acetylgalactosaminyltransferase* , 1997, The Journal of Biological Chemistry.

[30]  L. Tabak,et al.  Cloning and expression of mouse UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferase-T3. , 1996, Biochemical and biophysical research communications.

[31]  L. Tabak,et al.  Molecular cloning of a rat submandibular gland apomucin. , 1994, The Journal of biological chemistry.

[32]  L. Tabak,et al.  Separation of glycopeptides from in vitro O-glycosylation reactions using C18 cartridges. , 1993, Analytical biochemistry.

[33]  E. Farrow,et al.  Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaphyseal chondrodysplasia. , 2009, The Journal of clinical endocrinology and metabolism.

[34]  J. P. Hobson,et al.  Imaging specific cell surface protease activity in living cells using reengineered bacterial cytotoxins. , 2009, Methods in molecular biology.

[35]  L. Tabak,et al.  cDNA Cloning and Expression of a Novel UDP- N -acetyl- D -galactosamine:Polypeptide N -Acetylgalactosaminyltransferase* , 1997 .